Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:PTCT NYSE:RCUS NASDAQ:RNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$71.19-1.4%$69.82$47.86▼$107.37$3.95B0.28651,176 shs16,993 shsPTCTPTC Therapeutics$57.32-1.2%$49.09$30.59▼$58.73$4.56B0.531.09 million shs117,280 shsRCUSArcus Biosciences$11.61+0.4%$9.63$6.50▼$18.98$1.24B0.831.00 million shs52,178 shsRNAAvidity Biosciences$49.00+1.1%$38.82$21.51▼$56.00$6.32B0.991.85 million shs828,688 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+1.32%+2.72%+0.17%+5.96%+10.24%PTCTPTC Therapeutics+4.43%+16.51%+13.50%+11.28%+72.70%RCUSArcus Biosciences-0.58%+9.01%+21.16%+15.77%-29.10%RNAAvidity Biosciences+1.85%-0.23%+26.69%+33.75%+16.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$71.19-1.4%$69.82$47.86▼$107.37$3.95B0.28651,176 shs16,993 shsPTCTPTC Therapeutics$57.32-1.2%$49.09$30.59▼$58.73$4.56B0.531.09 million shs117,280 shsRCUSArcus Biosciences$11.61+0.4%$9.63$6.50▼$18.98$1.24B0.831.00 million shs52,178 shsRNAAvidity Biosciences$49.00+1.1%$38.82$21.51▼$56.00$6.32B0.991.85 million shs828,688 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+1.32%+2.72%+0.17%+5.96%+10.24%PTCTPTC Therapeutics+4.43%+16.51%+13.50%+11.28%+72.70%RCUSArcus Biosciences-0.58%+9.01%+21.16%+15.77%-29.10%RNAAvidity Biosciences+1.85%-0.23%+26.69%+33.75%+16.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.13Buy$114.3160.58% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$69.0020.39% UpsideRCUSArcus Biosciences 2.75Moderate Buy$21.1482.19% UpsideRNAAvidity Biosciences 3.06Buy$67.0036.73% UpsideCurrent Analyst Ratings BreakdownLatest RCUS, RNA, PTCT, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$118.008/20/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $73.008/20/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$76.00 ➝ $71.008/20/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$82.00 ➝ $76.008/8/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$70.008/8/2025PTCTPTC TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/8/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$60.00 ➝ $63.008/8/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$78.00 ➝ $79.008/8/2025RNAAvidity BiosciencesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$70.00 ➝ $75.008/8/2025RNAAvidity BiosciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$59.00 ➝ $62.008/8/2025RNAAvidity BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00(Data available from 9/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M36.58N/AN/A$8.41 per share8.46PTCTPTC Therapeutics$806.78M5.64N/AN/A($14.24) per share-4.03RCUSArcus Biosciences$258M4.79N/AN/A$5.30 per share2.19RNAAvidity Biosciences$10.90M578.36N/AN/A$11.94 per share4.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.978.24N/AN/A35.65%-106.31%30.61%11/6/2025 (Estimated)RCUSArcus Biosciences-$283M-$3.17N/AN/AN/A-109.56%-55.96%-25.73%11/5/2025 (Estimated)RNAAvidity Biosciences-$322.30M-$3.56N/AN/AN/A-4,247.77%-33.45%-30.22%11/6/2025 (Estimated)Latest RCUS, RNA, PTCT, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q2 2025PTCTPTC Therapeutics-$1.07-$0.83+$0.24-$0.83$173.01 million$178.88 million8/6/2025Q2 2025RCUSArcus Biosciences-$1.14-$1.1053+$0.0347N/A$32.86 million$160.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ARNAAvidity BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81PTCTPTC TherapeuticsN/A3.623.57RCUSArcus Biosciences0.184.504.50RNAAvidity BiosciencesN/A9.269.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%PTCTPTC TherapeuticsN/ARCUSArcus Biosciences92.89%RNAAvidity BiosciencesN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx8.35%PTCTPTC Therapeutics5.50%RCUSArcus Biosciences9.60%RNAAvidity Biosciences3.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionablePTCTPTC Therapeutics1,41079.44 million75.07 millionOptionableRCUSArcus Biosciences500106.43 million96.21 millionOptionableRNAAvidity Biosciences190128.65 million123.73 millionOptionableRCUS, RNA, PTCT, and ACLX HeadlinesRecent News About These CompaniesAdage Capital Partners GP L.L.C. Has $63.35 Million Stock Position in Avidity Biosciences, Inc. $RNA5 hours ago | marketbeat.comAvidity Biosciences, Inc. (RNA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript5 hours ago | seekingalpha.comMPM Bioimpact LLC Has $21.08 Million Stake in Avidity Biosciences, Inc. $RNASeptember 4 at 7:02 AM | marketbeat.comFrazier Life Sciences Management L.P. Invests $15.50 Million in Avidity Biosciences, Inc. $RNASeptember 4 at 6:50 AM | marketbeat.comAvidity Biosciences CEO expects ‘lots of rumors’ about acquisition interestSeptember 4 at 2:30 AM | msn.comNorthern Trust Corp Sells 60,952 Shares of Avidity Biosciences, Inc. $RNASeptember 2 at 4:10 AM | marketbeat.comDriehaus Capital Management LLC Purchases 42,873 Shares of Avidity Biosciences, Inc. $RNAAugust 31, 2025 | marketbeat.comSiren L.L.C. Decreases Holdings in Avidity Biosciences, Inc. $RNAAugust 31, 2025 | marketbeat.comRafferty Asset Management LLC Sells 32,167 Shares of Avidity Biosciences, Inc. $RNAAugust 31, 2025 | marketbeat.comInsider Selling: Avidity Biosciences (NASDAQ:RNA) CEO Sells 25,000 Shares of StockAugust 30, 2025 | insidertrades.comInvesco Ltd. Purchases 193,376 Shares of Avidity Biosciences, Inc. $RNAAugust 28, 2025 | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferencesAugust 27, 2025 | prnewswire.comBI Asset Management Fondsmaeglerselskab A S Sells 52,463 Shares of Avidity Biosciences, Inc. $RNAAugust 27, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 295,275 Shares of Avidity Biosciences, Inc. $RNAAugust 26, 2025 | marketbeat.com771,158 Shares in Avidity Biosciences, Inc. $RNA Acquired by T. Rowe Price Investment Management Inc.August 26, 2025 | marketbeat.comRNA Stock Moves More Than 30% in a Week: What's Driving This Rally?August 25, 2025 | zacks.comNuveen LLC Invests $12.73 Million in Avidity Biosciences, Inc. $RNAAugust 24, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $102,451.20 in StockAugust 23, 2025 | insidertrades.comCandriam S.C.A. Increases Stock Position in Avidity Biosciences, Inc. $RNAAugust 23, 2025 | marketbeat.comWellington Management Group LLP Has $285.89 Million Stock Holdings in Avidity Biosciences, Inc. $RNAAugust 22, 2025 | marketbeat.comAberdeen Group plc Increases Holdings in Avidity Biosciences, Inc. $RNAAugust 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesDisney’s Iger-Led Turnaround Gains TractionBy Thomas Hughes | August 6, 20252 Powerful Forces Now Back Intel's TurnaroundBy Jeffrey Neal Johnson | August 20, 2025Lyft's Billion-Dollar Signal: Why Wall Street Is Betting BigBy Jeffrey Neal Johnson | August 19, 2025Chevron Stock Outlook: Dividend Growth Meets InflationBy Chris Markoch | August 28, 2025Mercury Systems Up 27%: Financials Send Investors a Clear SignalBy Jeffrey Neal Johnson | August 14, 2025RCUS, RNA, PTCT, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$71.18 -0.98 (-1.35%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.PTC Therapeutics NASDAQ:PTCT$57.32 -0.69 (-1.20%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Arcus Biosciences NYSE:RCUS$11.60 +0.05 (+0.39%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Avidity Biosciences NASDAQ:RNA$49.00 +0.53 (+1.10%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Affirm Crushes Earnings Expectations, Turns Bears into Believers Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Microsoft’s AI Push Beyond OpenAI Could Drive Next Breakout Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
